Our biosimilar rituximab could add to the cost-effective treatment alternatives for patients with DLBCL in India.doi:10.1007/s00280-023-04530-xPatel, AnkitBhatt, NirajPrakash, S. S.Biswas, GhanashyamNagarkar, RajnishRoy, BodhisattaSamal, Priyanka...
These packages are designed to offer cost-effective, time-saving solutions to meet small-scale rush needs in as fast as 8 days, with a sizable production capability for more than 5K samples. Now adding RushMab-Gene! With only 4 days, we can have 100ug transfection-grade expr... ...
chemical synthesis avoiding batch-to-batch variability of antibodies, introduction of modifications and functional groups as well as their cost-efficiency61. In contrast
Biosimilar Monoclonal Antibodies Market by Drug Class, Application - Global Forecast 2025-2030 Report 198 Pages October 2024 Global From €3894 Biosimilars Market by Product, Indication, Manufacturing - Global Forecast 2025-2030 Report 187 Pages ...
CN2 COST-EFFECTIVENESS ANALYSIS OF RITUXIMAB + CHOP VERSUS CHOP IN PATIENTS WITH AGGRESSIVE NONHODGKIN LYMPHOMACluster headacheparoxysomal hemicraniaSUNCT syndromeThe present study summarizes the authors' experience of the clinical profile of short-lasting trigeminal autonomic cephalgias (TAC) in Indian ...
Persistent CD-19 depletion by rituximab is cost-effective in maintaining remission in calcineurin-inhibitor dependent podocytopathycalcineurin inhibitorfocal segmental glomerulosclerosisminimal change diseaserituximabsteroid dependentsteroid resistantAim A significant proportion of patients with minimal change disease ...
On subgroup analysis, rituximab is significantly cost effective from a health system perspective [$12,832 (3392 to 22,272)], for studies using 3.5% discount rate [$15,468 (5973 to 24,963)] and a for a time horizon of less than 5years [$8496 (1547 to 15,445)]. In a separate ...
It revolutionized the treatment of non-Hodgkin's lymphoma with superior progression-free and overall survival. However, its prohibitively high cost makes it inaccessible to majority of patients in developing countries. Reditux (TM) (Dr. Reddy's Laboratories, India), a biosimilar, was introduced in...